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Calciphylaxis is a serious condition characterized by sized that Selye’s model did not exhibit the histology con-
sistently described with uremic calciphylaxis (i.e., small-necrosis of the skin and adipose tissue. It is seen mainly
in patients with end-stage renal disease (ESRD) on vessel calcification and intimal hypertrophy in association
with panniculitis and small-vessel thrombosis) [2].maintenance dialysis. Calciphylaxis, also known as cal-
cific uremic arteriolopathy (CUA), carries a high mortal-
ity rate, mainly due to secondary infections, sepsis, and
PATHOGENIC CONSIDERATIONS
ischemia.
It is important to review certain pathogenic factors.Seyle [1] first described in 1962 a syndrome in the
First, the presence of a uremic milieu together with aexperimental animal and postulated that two steps are
high Ca x P product has been in the majority of reportsrequired to produce ectopic systemic calcifications. First,
[2–5]. Diffuse vascular calcifications were frequentlya systemic sensitization induced by agents such as para-
noted in the early days of maintenance dialysis [6]. Extra-thyroid hormone (PTH), vitamin D, or a diet high in
skeletal calcifications were noted in 20% of dialysis pa-calcium (Ca) and phosphorus (P). Second, after a time
tients with secondary hyperparathyroidism (HPT) [6];interval (the “critical period”), exposure to appropriate
this number increased to 58% in patients with clinicalchallenging agents by subcutaneous injections resulted
evidence of HPT, and to 75% in patients with severein macroscopically visible deposits of calcium salts (hy-
overt HPT [7]. Still, even in the early days, at a timedroxyapatite) systemically, and at the site of injection
when secondary HPT was common, calciphylaxis waswithin two to three days. Challenging agents included
uncommon.local trauma, iron salt, egg albumin, polymyxin, and glu-
Second, the Ca content of the skin was an importantcocorticoids. Selye named the syndrome “calciphylaxis.”
pathogenic factor because it was noted to be high inA few years later a syndrome characterized by peripheral
dialysis patients developing calcific uremic arteriolopa-ischemic tissue necrosis, vascular calcification, and cuta-
thy (CUA) [8]. CUA also appeared to occur when a highneous ulcerations was reported in uremic patients.[2]
dialysate Ca concentration of 4.0 mEq/L was used. [9]Because of its resemblance to Selye’s animal model, it
In addition, a decrease in dialysate Ca dramatically im-was also named “calciphylaxis” [2]. However, the syn-
proved CUA in some patients, whereas a high dialysatedrome described in the uremic patient only resembles
Ca concentration aggravated soft tissue calcification [9].Selye’s model. Though a useful concept, the analogy to
Furthermore, CUA was associated with hypercalcemiaSelye’s model may not be warranted because the term
induced by large oral doses of calcium carbonate, and it“calciphylaxis” has pathogenic implications that have not
was reversed by discontinuing Ca carbonate [10]. It isbeen confirmed in humans. Thus, significant differences
worth emphasizing that the use of Ca-containing bindersexist between Selye’s model and uremic calciphylaxis.
is common, and that many dialysis patients still ingestThe former was characterized by metastatic systemic
large doses of elemental Ca. The long-term effect of thiscalcifications that developed after significant invasive
large Ca load on the dialysis population remains to bemanipulations of the animal model, but vascular calcifi-
established. It is striking that almost all patients de-cations were not present. The latter occur primarily in
scribed in recent years who developed CUA were ingest-the presence of uremia with abnormalities in divalent
ing Ca-containing binders.ions (i.e., hypercalcemia, hyperphosphatemia, and high
A third important pathogenic factor was the presencePTH), and most importantly, vascular calcifications were
of high PTH levels. Earlier, it appeared that HPT wasnoted at the lesions. Retrospectively, it appears that ure-
an important risk factor in the development of CUA [4].mic soft tissue calcification (tumoral calcinosis) is the
Gipstein et al [4] reported a series of patients with CUA,syndrome most analogous to Selye’s. It should be empha-
most with peripheral digital ulcers, in whom parathyroid-
ectomy (PTx) resulted in dramatic healing of the ulcers
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present in each patient at some point prior to the appear- necrosis of the skin become clinically apparent. Coates
et al [3] noticed a significant weight loss preceding theance of CUA. Later, hyperphosphatemia was also associ-
ated with CUA [6, 11]. In these patients, who had rela- development of the skin lesion in 7 of 16 patients. Fur-
thermore, Bleyer et al [5] in a logistic regression analysistively low PTH levels, appropriate phosphorus restriction
was shown to reverse CUA [5, 11]. identified obesity and low serum albumin as highly pre-
dictive of CUA. Others have noted an association with
insulin-dependent diabetes mellitus and CUA. Interest-
CLINICAL CONSIDERATIONS
ingly, in four patients the lesions developed in areas that
The skin lesions of calciphylxis usually begin as painful had served as sites of insulin injection [5].
nodules or violaceous mottling similar to livedo reticu- The evolving nature of CUA is reflected in our clinical
laris, or as painful panniculitis. The lesions may be found observations over the last five years of 22 patients with
in the distal extremities, involving the toes, fingers, or CUA 12]. Twenty patients were on HD and two had
ankles (acral lesions), or they may be localized proximal renal transplantations. All patients developed painful
to the knees and elbows, typically in areas rich in adipose livido retucularis. Eighteen patients had proximal skin
tissue [e.g., the thighs, buttocks, abdominal wall, and lesions (proximal CUA) and four had distal lesions (acral
breasts (proximal lesions)]. Occasionally they are bilat- CUA). Sixteen patients were morbidly obese. All pa-
eral and symmetrical. As the lesions progress and ex- tients had elevated Ca x P product in the past, but only
pand, they may become hemorrhagic, and deep ulcers four patients had an elevated PTH (870  234 pg/mL).
and eschars may develop. Dry gangrenous digits can On presentation, serum Ca, P, and PTH (250) were
occur. seemingly controlled in some patients; however, when
Histologically, the lesions are characterized by calcifi- compared with a matched (for comorbid factors) ESRD
cation of small subcutaneous arteries and arterioles, and population (100 patients), CUA patients had a higher
infarctions of the adjacent subcutis and skin. The primary serum Ca (corrected for serum albumin), phosphorus
lesion appears to be the accumulation of calcium salts (P), and Ca x P product. Most importantly, in the 16
in the media of the small arteries and arterioles. Subse- patients with proximal CUA, PTH levels were signifi-
quently, the intima is thickened by loose connective tis- cantly lower (P  0.01) than the control ESRD patients.
sue, which narrows the lumen, sometimes markedly, and Ten patients had previous parathyroidectomy (PTx) 1 to
compromises perfusion. 3 years prior to presentation. All patients were ingesting
The clinical picture of calciphylxis has evolved over large doses of Ca-containing phosphate binders (4.2 
the last three decades, and from the increase in number 2.1 g/elemental Ca). Two patients were taking oral cal-
of cases reported, the incidence of calciphylaxis may be triol (.5 g/day) and 15 were on intravenous calcitriol
on the rise. In the first descriptions in the late 1960s and (1–3g), despite the relatively low PTH (mean 250 pg/mL).
early 1970s, calciphylaxis was noted to predominantly Fourteen patients had skin biopsies that showed panni-
involve distal sites in uremic patients with clinically sig- culitis, extensive Ca deposits within arteriole size and
nificant hyperparathyroid bone disease and elevated Ca small vessel wall with endovascular fibrosis and fat necro-
x P product. A link between calciphylaxis and HPT was sis. The four patients with high PTH levels (mean PTH
further supported by the early observation that PTx dra- 800 pg/mL) underwent PTx, which resulted in resolution
matically improved the syndrome [4]. Thus, ulcerations of the lesions in two patients, and improvement in one.
that had persisted for months healed dramatically within In 10 patients with proximal CUA and relatively low
weeks following PTx [4]. PTH, Ca-containing binders were switched to Renagel
In the last 10 years, the clinical features of CUA have and HD was performed five days/week using a low dialy-
changed. At present, the great majority of the cases de- sate Ca (1 or 2 mEq/L). Five patients had significant
scribes the lesions proximally, particularly in Caucasian improvement in CUA lesions and two patients had com-
women. Obesity has been recently described as a predis- plete resolution of the lesions.
posing factor. Hypoalbuminemia and diabetes may be Local trauma, such as subcutaneous injections of hepa-
increased risk factors for calciphylaxis. With the advent rin or iron dextran, may also be precipitating factors in
of calcitriol and better control of HPT, other factors have the local development of CUA. [5]. The relative risk of
surfaced and become more relevant in the triggering of CUA increased as weight increased. This is important
CUA. As reported by Coates et al [3] and Bleyer et al because severe morbid obesity is uncommon in dialysis
[5], the presence of obesity is an important predisposing patients and these patients may be easily identified. The
factor to developing CUA, especially in white women. impression is that patients with proximal calciphylaxis
Morbid obesity was present in 11 of our 14 patients have a poorer prognosis than those with acral CUA.
(79%) with CUA [12]. Supposedly, areas rich in adipose Thus, Hafner et al [13] evaluated the role of PTx in 38
tissue may be more prone to small-vessel damage, which of 58 patients who had survived, compared with 13 of
37 patients who did not undergo PTx [13]. Most impor-may promote calcification before cutaneous lesions and
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tantly, 40 of the 53 patients (75%) with distal location proved CUA in continuous ambulatory peritoneal dial-
ysis (CAPD) patients [16].of necrosis survived, compared with 11 of 42 patients
(26%) with proximal CUA (P  0.00001).
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